VedaBio

What VedaBio does

VedaBio is a privately held biotechnology company headquartered in San Diego, California, developing the CRISPR Cascade™ platform for ultra-rapid molecular detection. The platform employs two engineered CRISPR ribonucleoprotein complexes — RNP1 for target identification and RNP2 for signal amplification via a positive feedback loop — enabling analytical turnaround times under one minute with PCR-level accuracy and without the need for target amplification. The technology supports massive multiplexing by pooling multiple targets in a single reaction, addressing limitations of PCR where assay complexity scales poorly with target count. A non-exclusive license from Mammoth Biosciences (Sept 2025) augments the company's CRISPR intellectual property base.

VedaBio is pre-commercial and plans to monetize the platform primarily through hardware sales (instruments and consumables) targeted at decentralized clinical settings — urgent care, outpatient clinics, and point-of-care environments — with syndromic respiratory infection testing as an initial focus area. Secondary addressable markets include research tools, therapeutics (companion diagnostics), and industrial applications (agriculture, environmental monitoring, food safety). The go-to-market is structured around enterprise field sales, with a strategic agreement with Siemens Healthineers (Sept 2025, up to $25M combined with Series A extension) intended to validate the amplification-free technology and accelerate product development for decentralized diagnostics.

The company was founded in 2023 and has raised over $65 million across two funding tranches, led by OMX Ventures with participation from family offices including Kleinmuntz Associates and a strategic investment from Siemens Healthineers. Leadership includes former executives from BioFire Diagnostics, bioMérieux, Thermo Fisher Scientific, New England Biolabs, and Sherlock Biosciences, and a Scientific Advisory Board chaired by Daniel Durocher with members Patrick Hsu, David Perlin, and co-founder Rashid Bashir. The company currently has 11–50 employees and a single San Diego headquarters.

Name

VedaBio

Legal name

VedaBio, Inc.

Website

https://vedabio.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

VedaBio is a pre-commercial San Diego biotechnology company developing the CRISPR Cascade™ molecular detection platform, which delivers sub-one-minute, PCR-accurate, highly multiplexed results without target amplification. It targets decentralized clinical diagnostics, research tools, therapeutics, and industrial applications.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro industry

PRIMARYHLAAALAL

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)

Healthcare & Life Sciences/Biotechnology & Biologics/Diagnostics (Biotech-related)

SECONDARYHLAAAIAG

CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

SECONDARYHLAGAIAF

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Laboratory Equipment, Instruments & Consumables

SECONDARYHLAAALAA

Molecular Diagnostics (PCR/qPCR, NGS-based assays)

Healthcare & Life Sciences/Biotechnology & Biologics/Diagnostics (Biotech-related)

Keywords

• CRISPR diagnostics
• Molecular detection platform
• Point-of-care testing
• Infectious disease diagnostics
• Multiplexed nucleic acid detection

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Molecular Diagnostics Platform and Tests: VedaBio plans to commercialize its CRISPR Cascade platform for molecular detection applications including diagnostics, therapeutics, research tools, and industrial applications. The company is developing tests for infectious disease detection in decentralized healthcare settings, with syndromic respiratory infection testing mentioned as an initial focus area.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

VedaBio is developing the CRISPR Cascade, a molecular detection platform that uses engineered CRISPR enzyme complexes (RNPs) to identify nucleic acid targets and amplify detection signals through a positive feedback loop without target amplification. The platform enables ultra-rapid (sub-one-minute) analytical turnaround times, PCR-level accuracy, and massive multiplexing scalability for applications in clinical diagnostics, research tools, therapeutics, and industrial testing.

Product overview

VedaBio offers a single unified platform product called CRISPR Cascade™, a molecular detection platform that delivers ultra-rapid, highly multiplexed analyte detection without the need for target amplification. The platform uses engineered CRISPR enzymes with a two-ribonucleoprotein (RNP) system where RNP1 identifies target sequences and initiates detection signals while RNP2 amplifies signals in a positive feedback loop. This enables analytical turnaround times under 1 minute with PCR-level accuracy, targeting applications across diagnostics, therapeutics, and research tools.

Differentiator

Problem solved

Functional benefit

Products and services

• CRISPR Cascade Molecular detection platform that employs two engineered CRISPR ribonucleoprotein complexes (RNP1 and RNP2) in a positive feedback signal amplification loop. RNP1 identifies a nucleic acid target and initiates a detection signal, while RNP2 specifically amplifies the signal, enabling analytical turnaround times under one minute with PCR-level accuracy and massive multiplexing without target amplification. Targeted at clinical diagnostics, research tools, therapeutics, and industrial molecular detection applications.

Quantifiable outcome

• Analytical turnaround time of less than 1 minute for molecular detection
• +2 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• Siemens HealthineerscoreStrategic or Co-development Partner · 23 September 2025Strategic agreement with Siemens Healthineers totaling up to $25 million (combined with Series A extension) to advance VedaBio's CRISPR-based molecular detection platform. The partnership aims to validate VedaBio's amplification-free technology and strengthen product development in decentralized diagnostics, particularly for rapid infectious disease testing.
• Mammoth BiosciencescoreTechnology or Integration · 9 September 2025Non-exclusive license agreement for the use of select CRISPR-based technologies in diagnostic applications. The agreement provides VedaBio with access to foundational CRISPR intellectual property, enabling acceleration of development of purpose-built diagnostic solutions.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Cepheid (Danaher): Cepheid's GeneXpert is the gold-standard rapid molecular diagnostics platform with deep installed base across hospitals and decentralized settings. As a broad incumbent in rapid molecular testing, it represents the primary infrastructure VedaBio must displace or partner with via Siemens.
• Abbott Molecular: Abbott's m2000 and Alinity m molecular diagnostics platforms serve high-volume clinical labs. VedaBio COO Maurice Exner previously led product development/M&A integration at Abbott Point of Care, indicating close executive-level familiarity with the competitive landscape.
• Qiagen: Qiagen provides sample-prep and PCR-based molecular testing solutions for infectious disease and research. Its QIAstat-Dx platform competes directly in syndromic respiratory testing, the initial application area VedaBio has prioritized.
• Hologic: Hologic's Panther and Panther Fusion systems serve high-throughput molecular diagnostics, with a portfolio that competes directly with the syndromic respiratory and infectious disease testing menu VedaBio plans to enter. VedaBio's COO Maurice Exner was previously VP R&D at Hologic.
• Roche Diagnostics: Roche's cobas and Liat systems are established rapid molecular diagnostics platforms in centralized and decentralized settings. As a global diagnostics incumbent with deep R&D and commercial reach, it represents both a competitor and a potential strategic acquirer for CRISPR-based diagnostics platforms.
• BioFire Diagnostics (bioMérieux): BioFire is the dominant syndromic molecular diagnostics incumbent whose FilmArray platform is the primary commercial benchmark VedaBio aims to disrupt. Several VedaBio executives (Rasmussen, Jones, Millward) previously led BioFire, making it the most relevant competitive reference point for VedaBio's commercialization trajectory.

Direct peers

• Mammoth Biosciences: Mammoth develops CRISPR-based diagnostics (DETECTR) using Cas12 and Cas14 enzymes and is both a licensor of foundational CRISPR IP to VedaBio (Sept 2025) and a competitor in CRISPR diagnostics. Both pursue amplification-free, multiplexed molecular detection for clinical and research applications.
• Sherlock Biosciences: Sherlock is the closest CRISPR-based molecular diagnostics peer, developing CRISPR-Cas12 and Cas13 platforms (SHERLOCK, INSPECTR) for infectious disease and oncology. Both target decentralized, amplification-free molecular detection, and Sherlock's former CSO Maurice Exner is now COO at VedaBio, highlighting the close technical and talent overlap.
• Caspr Biotech: Caspr is an emerging CRISPR diagnostics company developing Cas13-based molecular detection for infectious disease and antimicrobial resistance. It is an emerging direct competitor focused on similar amplification-free, rapid point-of-care applications.

Others

• Twist Bioscience: Twist is a synthetic biology and DNA synthesis company enabling CRISPR screens, antibody libraries, and NGS target enrichment. While not a direct competitor in diagnostics, Twist is a strategic adjacency in CRISPR-driven life science tools and a portfolio company of OMX Ventures (VedaBio's lead investor).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/vedabioinc

Revenue estimate

Valuation estimate

Number of profiles

Profiles23 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VedaBio